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ABSTRACT
The Cancer Genome Atlas (TCGA) data indicate that high MDM2 expression 
correlates with all subtypes of breast cancer. Overexpression of MDM2 drives breast 
oncogenesis in the presence of wild-type or mutant p53 (mtp53). Importantly, 
estrogen-receptor positive (ER+) breast cancers overexpress MDM2 and estrogen 
mediates this expression. We previously demonstrated that this estrogen-MDM2 
axis activates the proliferation of breast cancer cell lines T47D (mtp53 L194F) and 
MCF7 (wild-type p53) in a manner independent of increased degradation of wild-
type p53 (ie, p53-independently). Herein we present data supporting the role of the 
estrogen-MDM2 axis in regulating cell proliferation and mammary tissue architecture 
of MCF7 and T47D cells in a p53-independent manner. Inducible shRNA mediated 
MDM2 knockdown inhibited colony formation in soft agar, decreased mass size and 
induced lumen formation in matrigel and also significantly reduced mitosis as seen 
by decreased phospho-histone H3 positive cells. The knockdown of MDM2 in both cell 
lines decreased Rb phosphorylation and the level of E2F1 protein. This signaling was 
through the estrogen receptor because fulvestrant (a selective estrogen receptor 
degrader) decreased MDM2 protein levels and decreased phosphorylation of Rb. 
Taken together these data indicate that in some ER+ breast cancers the estrogen-
MDM2-Rb-E2F1 axis is a central hub for estrogen-mediated p53-independent signal 
transduction. This is the first indication that estrogen signaling utilizes the estrogen-
MDM2 axis to provoke phosphorylation of Rb and increase E2F1 while promoting 
abnormal mammary architecture.
INTRODUCTION
A majority of breast cancers are estrogen–receptor 
alpha positive (ER+) and many of these are resistant to 
therapies targeting their hormone receptor status [1]. 
Many ER+ breast cancers have MDM2 overexpression 
suggesting that MDM2 is an ER+ axis driver oncogene 
that can be targeted for cancer therapy [2–4]. MDM2 
overexpression is found in many different types of cancers 
[5, 6]. Some cancer patients with MDM2 overexpression 
have a worse prognosis than patients with cancers that 
do not have such overexpression [5]. Therefore it is not 
surprising that MDM2 expression is a negative prognostic 
marker for breast cancer [7]. ER+ cells exposed to estrogen 
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show an increase in their transcription of mdm2 and 
increased MDM2 protein [8–11]. The mdm2 gene contains 
a single nucleotide polymorphism, SNP 309, where T is 
changed to G thereby further increasing estrogen activated 
MDM2 expression by increased recruitment of the Sp1 
transcription factor to the promoter region of the gene 
[9, 12]. This mdm2 SNP309 G allele accelerates tumor 
formation in a gender specific and hormone dependent 
manner [9]. While estrogen signaling up-regulates MDM2, 
it has not been determined if MDM2 is required for the 
estrogen-mediated phenotypic changes that are associated 
with tumorigenesis. Herein we investigate the estrogen-
MDM2 axis as a pathway that functions in some ER+ cells 
to promote p53-independent tumorigenic outcomes.
There are significant pieces of evidence showing that 
MDM2 has strong cancer promoting properties that are 
independent of degrading p53 [11, 13–16]. Our previous 
work uncovered that estrogen signaling activates MDM2-
mediated breast cancer proliferation in a p53-independent 
manner [11]. Most notably recent work has documented 
that estrogen receptor alpha mediates the p53-independent 
overexpression of both MDM2 and MDM4 in human 
breast cancers [13]. MDM2 expression in p53-null mice 
alters the tumor spectrum and rapidly promotes tumor 
formation [17]. Moreover forced MDM2 overexpression 
in both wild-type and p53-null mammary glands promotes 
cell cycle progression into S phase [18]. Particularly, 
proliferative targets of MDM2 include the stimulation of 
E2F1 transcriptional activity [19], increased E2F1 protein 
stability [20], disruption of the Rb-E2F1 complex and 
inhibition of tumor suppressive functions of Rb [21–23]. 
Estrogen treatment induces cell cycle progression through 
promoting the G1 to S phase transition [24] and promotes 
Rb phosphorylation [25]. This is also seen in prostate 
cancer cells where MDM2 depletion reduces E2F1 and 
phosphorylated Rb [26]. However, the connection between 
estrogen signaling, MDM2, and the Rb-E2F1 pathway 
has never been shown. We hypothesized that estrogen 
signaling mediated the disruption of mammary tissue 
architecture, and increased proliferative outcomes, through 
an MDM2-Rb-E2F1 axis.
One of the characteristics of malignancy is the 
disruption of normal mammary tissue architecture in 
the specific context of the extracellular matrix [27]. The 
central aspect of the mammary architecture is the acinus, 
which forms terminal ductal lobular units. Each acinus 
has a hollow lumen lined by a single layer of epithelial 
cells. This in vivo glandular architecture is lost in 2D 
culture due to loss of in vivo cell-to-cell communication 
and interactions with extracellular matrix proteins. This 
structure can be recapitulated when normal mammary 
epithelial cells are grown in 3D laminin-rich matrigel. 
Malignant cells grown in matrigel display a disrupted 
architecture and form disorganized colonies with a 
loss of tissue polarity and filled lumen [27]. Herein we 
investigated if in 3D matrigel conditions the estrogen-
MDM2 signaling axis in the MCF7 and T47D colonies 
contributed to the filled lumen phenotype. We observed 
that MDM2 was required for blocking hollow lumen 
formation. When MDM2 was knocked down in cells grown 
in matrigel, the colonies exhibited hollow lumen formation 
and reduced the number of cells that were phospho-histone 
H3 positive. Moreover, MDM2 knockdown in T47D and 
MCF7 cells grown with estrogen in 2D conditions showed 
decreased phosphorylation of Rb. The estrogen-MDM2-
Rb-E2F1 axis was blocked in the presence of the estrogen 
receptor antagonist fulvestrant. We show for the first 
time that at least in some cases the estrogen-MDM2 axis 
participates in a pathway that disrupts mammary tissue 
architecture, does not target p53 for degradation, and 
promotes activation of the E2F1 pathway.
RESULTS
MDM2 is required for estrogen to increase 3D 
colony size of estrogen receptor-positive breast 
cancer cells
To determine if estrogen signaling for tumorigenic 
properties requires the p53-independent MDM2 pathway 
we evaluated the effect of MDM2 knockdown on estrogen 
driven MCF7 and T47D proliferation in soft agar. These 
ER+ breast cancer cell lines carry the mdm2 SNP309 T 
to G change [9, 10, 12] and estrogen treatment induces 
their anchorage-independent cell growth in soft agar 
[28]. T47D cells express mtp53 L194F that does not 
activate transcription of p53 targets and also does not 
have oncogenic gain-of-function activity [29]. Estrogen 
treatment increases the p53-independent MDM2 signaling 
in T47D cell lines and also in MCF7 cells with wild-type 
p53 [10, 11]. To investigate how the estrogen-mediated 
increase in MDM2 protein affected anchorage independent 
growth of MCF7 and T47D cells we depleted MDM2 
using a mir30-based shRNA targeting strategy (described 
in [11]). We evaluated MDM2 knockdown by western 
blots for cells grown in 2D culture as shown in Figures 
4–6. Figures 4–6 are reflective of all MDM2 knockdown 
results. We observed a significant decrease in the size 
and number of colonies formed in soft agar with MDM2 
knockdown (Figure 1A and 1B). Representative images 
of the colonies formed by T47D with and without shRNA 
induction are shown in Figure 1C. In order to test the 
influence of MDM2 on 3D culture colony size through an 
additional method we examined the growth of MCF7 and 
T47D cells in matrigel.
Matrigel conditions allow cells to recapitulate in 
vivo mammary glandular architecture [30]. We previously 
documented that MDM2 knockdown in MCF7 and T47D 
cells leads to decreased proliferation and for MCF7 cells a 
reduction in large size masses in matrigel [11]. We studied 
the p53-independent role of MDM2 on T47D colonies 
formed in 3D matrigel culture conditions to determine the 
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biological significance of estrogen signaling through the 
MDM2 pathway. Reduced MDM2 caused a decrease in 
matrigel colony size (Figure 1D), and this agreed with the 
results presented for reduction of large soft agar colony 
formation shown in Figure 1A and 1B. We stratified the 
T47D masses into 5 different categories (Figure 1D, very 
small (yellow), small (red), intermediate (green), large 
(purple) and very large (blue)). MDM2 knockdown caused 
a robust decrease in large and very large masses and an 
increase in very small and small masses. The T47D.
vector control cell line did not produce small masses. 
The clonal T47D.shmdm2 cell line had some very small 
and small masses even without shRNA induction. This 
leaky phenotype of the T47D.shmdm2 was reproducible, 
Figure 1: MDM2 depletion in estrogen-treated breast cancer cells inhibits colony formation in 3D culture conditions. 
(A) Number of large colonies (50μm or larger) determined by counting the colonies of MCF7 cells when grown in soft agar in the presence 
of estrogen and in the presence or absence of shRNA induction (viewed by inverted fluorescence microscope). Average of three independent 
experiments are shown. The number of colonies for 3 independent experiments were as follows: control vector –shRNA induction (160, 158, 
175), control vector + shRNA induction (153, 151, 197), mdm2shRNA –shRNA induction (140, 137, 200) and mdm2shRNA + shRNA induction 
(17, 11, 8). The p-value determined by 2-tailed Student t-test comparing with and without MDM2 knockdown was p-value=0.002. (B) Number 
of large colonies (100μm or larger) determined by counting the colonies of T47D cells when grown in soft agar in the presence of estrogen 
and in the presence or absence of shRNA (viewed by inverted fluorescence microscope). Average of three independent experiments are shown. 
The number of colonies for 3 independent experiments were as follows: control vector –shRNA induction (220, 191, 70), control vector + 
shRNA induction (202, 195, 33), mdm2shRNA –shRNA induction (166, 175, 69) and mdm2shRNA + shRNA induction (27,20, 9). The p-value 
determined by 2-tailed Student t-test comparing with and without MDM2 knockdown was p-value=0.02. (C) Representative images of colonies 
that T47D cells formed in soft agar in the presence or absence of MDM2 knockdown. (D) T47D cells grown in matrigel for 3 weeks in presence 
of estrogen and in presence or absence of 4μg/ml doxycycline, were fixed and stained with propidium iodide. Colony masses were categorized in 
5 different groups and the number of masses in each group were counted and presented as percentages in the total population. This is an average 
of two independent experiments. The total number of masses scored for 2 independent experiments were control vector –shRNA induction (20, 
15), control vector + shRNA induction (25, 27), mdm2shRNA –shRNA induction (93, 95) and mdm2shRNA + shRNA induction (86, 83). The 
p-value was determined by 2-tailed Student t-test. The p-value for large and small colonies for comparisons with and without MDM2 knockdown 
were p-value=0.03 and p-value=0.05 respectively. Two independent scorers counted the numbers of colonies for each independent experiment.
Oncotarget47919www.impactjournals.com/oncotarget
and documented by two independent scorers for two 
independent experiments. We saw MDM2 knockdown 
decreased colony size of MCF7 and T47D cells in two 
mechanistically different experiments, repeated multiple 
times, and with multiple scored colonies.
MDM2 knockdown in T47D cells grown in 
matrigel promotes lumen formation
When T47D cells are grown in matrigel, they have a 
cancer mass morphology with disrupted architecture and 
filled lumen [30]. From the average of two independent 
experiments we observed that MDM2 depletion reverted 
this phenotype to become more normal (Figure 2). With 
mdm2 knockdown, and not in vector induced control 
samples, we observed a significant average increase in the 
number of masses having hollow ductal lumen architecture 
that showed a degree of luminal clearance (Figure 2A). 
We observed different luminal clearance phenotypes. 
A small proportion had perfect hollow lumen architecture 
(representative image shown in Figure 2B, top row), 
and many had variations with multiple hollow regions 
(representative image shown in Figure 2B, middle row). 
When MDM2 was not depleted there were significantly 
less masses with hollow lumen (Figure 2A see vector 
control results and MCF7.shmdm2 no induction results 
and Figure 2B, bottom row for representative image). This 
result was recapitulated in the ER+ MCF7 breast cancer 
cells (Supplementary Figure 1A and 1B). This shows that 
in some ER+ breast cancer cells the knockdown of MDM2 
can revert the tumorigenic 3D filled lumen phenotype to 
a hollow lumen phenotype. The fact that this occurs in 
T47D cells with mtp53 supports our earlier finding that 
the estrogen-MDM2 axis works, at least in part, through a 
wild-type p53-independent pathway [11].
MDM2 knockdown inhibits mitosis in 3D cell 
culture condition
Mitosis-specific phosphorylation of histone H3 can 
be used as an indicator of cells undergoing mitosis [31]. 
We asked if the luminal clearance phenotype associated 
with decreased mitotic cells in matrigel masses. To do this 
we carried out two biological replicates for two different 
knockdown strategies and probed the masses with mitosis-
specific anti-phospho-histone H3 followed by analysis 
with confocal microscopy. MDM2 knockdown resulted 
in a dramatic decrease in the average number of mitotic 
cells observed in matrigel masses derived from T47D 
cells with inducible MDM2 knockdown (Figure 3A) 
and masses derived from T47D cells with constitutive 
MDM2 knockdown (Figure 3B). A representative image 
Figure 2: MDM2 depletion in ER+ breast cancer cells with mutant p53 leads to formation of lumen and reverts mammary 
architecture towards a normal state. (A) T47D cells grown in matrigel for 3 weeks in presence of estrogen and in the presence or 
absence of 4 μg/ml dox, were fixed, stained with F-Actin and mounted with DAPI containing mounting media. Confocal z-stack images were 
acquired. Masses with lumen were counted and presented as percent of total number of masses grown in 3D matrigel. An average of two 
independent experiments are shown. The number of masses counted for 2 independent experiments were control vector -shRNA induction 
(21, 41), control vector +shRNA induction (21, 47), mdm2shRNA -shRNA induction (31, 46) and mdm2shRNA +shRNA induction (31, 
62). The p-value determined by 2-tailed Student t-test comparing with and without MDM2 knockdown was p-value=0.01. Two independent 
scorers counted the numbers of masses for each independent experiment. (B) A representative image from confocal immunofluorescence 
microscopy showing a single slice from z-stack of DAPI, GFP and F-Actin of estrogen treated inducible clonal T47D.shmdm2 cells grown 
in 3D-matrigel in the presence or absence of 4μg/ml doxycycline (dox) for 3 weeks. The top and middle rows show hollow lumen and ductal 
lumen respectively in the presence of shRNA expression to mdm2; the GFP (green) indicates shRNA induction to mdm2. The third row shows 
mass structure (disruption of normal mammary glandular architecture) in the absence of shRNA expression to mdm2.
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of inducible clonal T47D.shmdm2 cells is shown in 
Figure 3C. In MCF7 cells with MDM2 knockdown we 
also observed a similar decrease in cells staining with 
anti-phospho-histone H3 (Supplementary Figure 1C and 
1D). This supports several studies that have shown MDM2 
overexpression drives cell cycle progression into S phase 
of the cell cycle [18, 32]. We tested the hypothesis that the 
estrogen-MDM2 axis drives the T47D cells into S phase 
by carrying out fluorescence activated cell sorting (FACS) 
on cells grown in standard 2D culture with estrogen with 
and without MDM2 depletion (Figure 3D). As predicted, 
estrogen treatment increased the number of S phase 
cells detected by FACS analysis and MDM2 knockdown 
significantly reduced the S phase percentage (Figure 3D). 
Together our data suggest MDM2 up-regulation is critical 
for the estrogen-driven S-phase entrance as well as the 
Figure 3: MDM2 knockdown impedes mitosis and significantly decreases the number of estrogen-driven S phase cells. 
(A) & (B) T47D cells ((A) inducible shmdm2 clonal and vector pool; (B) constitutive shmdm2 and vector pool) grown in the presence 
of estrogen in 3D matrigel for 3.5 weeks. The cells were fixed, permeabilized, blocked, stained with phospho-histoneH3 antibody and 
mounted with DAPI containing mounting media. Images were taken with confocal microscope. Quantitative analysis of phospho-histone 
H3 positive cells were performed by capturing optical Z-stack sections of masses and dividing the number of positive phospho-histone 
H3 cells by the total number of masses. (A) The number of masses counted in each group for 2 independent experiments were control 
vector -shRNA induction (29, 30), control vector +shRNA induction (30, 30), mdm2shRNA -shRNA induction (29, 30) and mdm2shRNA 
+shRNA induction (30, 30). (B) The number of masses counted in each group for 2 independent experiments were control vector (49, 60) 
and shmdm2 (48, 60). Average of two independent experiments are shown for each knockdown method. The p-value determined by 2-tailed 
Student t-test comparing with and without MDM2 knockdown was p-value=0.001 (A) and p-value=0.009 (B). Two independent scorers 
counted the numbers of masses for each independent experiment. (C) Representative confocal Z-stack image (single slice) showing DAPI, 
phospho-histone H3 and GFP in estrogen-treated inducible clonal T47D.shmdm2 cells in the presence and absence of 4μg/ml doxycycline. 
(D) Cell cycle analysis by FACS (Fluorescence Activated Cell Sorting). T47D cells were harvested, fixed and stained with propidium iodide 
and subjected to cell cycle analysis by FACS. Data are presented as percent of cells in S phase in a total population of 10,000 cells and 
analyzed by FACS in each group. Average of 4 independent experiments are shown. The p-value was determined by 2-tailed Student t-test 
and * represents a p-value ≤ 0.05
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disruption of mammary architecture. Interestingly, from 
four independent biological replicates with MDM2 
knockdown the S phase was the only stage that showed a 
statistically significant reduction.
The estrogen-mediated proliferative advantage is 
through an MDM2-Rb-E2F1 pathway
E2F1 is known to promote cell cycle progression 
so we tested if Rb phosphorylation and E2F1 protein 
levels were changed by estrogen treatment and if MDM2 
knockdown caused reversion. Estrogen treatment of T47D 
cells reproducibly increased MDM2 protein and this was 
reduced by shmdm2 induction to knockdown MDM2 
(Figure 4A, lanes 1-8 top panel). Importantly estrogen 
treatment increased phosphorylated Ser807/Ser811 Rb 
protein levels (which correlates with activation of the 
E2F pathway) and this phosphorylation was decreased 
by MDM2 knockdown (Figure 4A, lanes 1-8 phospho 
Rb panel). We detected a reduction of the lower 110 kD 
phospho Rb band as well as multiple higher migrating 
forms (Figure 4A, phospho Rb panel, compare lanes 7 and 
8). The MDM2 knockdown also resulted in a decrease in 
E2F1 protein (Figure 4A, E2F1 panel, compare lanes 5 and 
6, and lanes 7 to 8). Estrogen treatment caused an increase 
in the level of mtp53 and this mtp53 level was unchanged 
by the knockdown of MDM2. We used imageJ analysis 
to quantify the levels of MDM2, phosphorylated Ser807/
Ser811 Rb, and E2F1 from three independent biological 
replicates for T47D.shmdm2 western blots (Figure 4B). 
MDM2 knockdown caused a statistically significant 
reduction of MDM2 and E2F1 and a strong reduction in 
phosphorylated Rb that was not statistically significant. 
Using a different knockdown method we further validated 
the estrogen-MDM2-Rb-E2F1 axis from three biological 
replicates of the T47D cells with constitutive MDM2 
knockdown (Figure 4C and 4D). For this alternative 
knockdown method we observed that constitutive MDM2 
knockdown resulted in a statistically significant decrease 
in the estrogen-driven phosphorylation of Rb. In these 
conditions we detected only the predominant lower Rb band 
at 110 kD (Figure 4C). This detection of only the lower Rb 
form was due to a lower exposure of the western blot.
We investigated the estrogen-MDM2 axis signaling 
to Rb in MCF7 cells. We previously published that 
exposing MCF7.shmdm2 cells to estrogen increases the 
amount of MDM2 protein level and depletion of the 
MDM2 does not increase the p53 protein level [11]. In 
this experiment, in support of the T47D data, estrogen 
treatment of the control and MCF7.shmdm2 cells increased 
MDM2, phosphorylated Rb, total Rb and E2F1 (Figure 5A 
and 5B) and induction of mdm2 shRNA reduced MDM2 
protein, phosphorylated Rb and E2F1 protein levels 
(Figure 5A compare lanes 3 and 4 to lanes 7 and 8 and 
see 5B). ImageJ analysis of four independent biological 
replicates with MDM2 knockdown indicated a statistically 
significant reduction in E2F1 and a strong reduction in 
phosphorylated Rb (Figure 5B).
Fulvestrant decreases MDM2 levels and blocks 
phosphorylation of Rb
Fulvestrant is a clinically used ER antagonist 
that promotes MDM2 protein turnover [33]. MDM2 
has been shown to promote tamoxifen resistance and 
therefore combination-fulvestrant treatments have been 
proposed for patients with advanced breast cancer as a 
way to target the MDM2 axis [13, 33]. We investigated 
if fulvestrant could block the estrogen-MDM2-mediated 
phosphorylation of Rb. We observed that fulvestrant 
treatment of T47D.shmdm2 cells downregulated both 
MDM2 and phosphorylated Rb levels (Figure 6A, 
compare lanes 1 and 3). This down regulation was 
slightly improved by shmdm2 induction (Figure 6A, 
phospho Rb panel, lane 4). This decrease was observed 
in three independent biological replicates with fulvestrant 
alone showing a statistically significant decrease and 
the combination of MDM2 knockdown plus fulvestrant 
showing a trend for further reduction (Figure 6A, dot plot 
of the three experiments shown below western blot). We 
were interested in examining whether the combination 
of fulvestrant and MDM2 knockdown also caused a 
further reduction of cell viability compared to fulvestrant 
treatment alone. We saw that in the presence of estrogen 
the mitochondrial activity was statistically significantly 
reduced by either MDM2 knockdown or fulvestrant 
treatment almost to the same extent (Figure 6B). 
When cells were subjected to MDM2 knockdown and 
fulvestrant treatment together there was more decrease 
in mitochondrial activity than with either alone, but this 
was not statistically significant (Figure 6B). Therefore 
fulvestrant effectively blocks the estrogen-MDM2-
mediated axis. We wondered if estrogen signaling to 
MDM2 increased proliferation by blocking cell death. 
We carried out live cell imaging to determine if either 
MDM2 knockdown, or fulvestrant treatment, increased 
cell death (Figure 6C, blue staining detects nuclei and red 
staining showing dead cells). Neither MDM2 knockdown 
nor fulvestrant treatment resulted in an increase in dead 
cells further supporting that the pathway targeted by the 
estrogen-MDM2 axis was involved in cell cycle regulation 
(Figure 6C T47D.shmdm2 and T47D vector control).
MDM2 drives Rb phosphorylation
Our data suggested that the up-regulation of MDM2 
might have a direct role in increasing the phosphorylation of 
Rb because estrogen stimulation of MCF7 and T47D cells 
required MDM2 for the increased phosphorylation of Rb. 
We wondered if MDM2 protein directly promoted signal 
transduction for increased phosphorylation of Rb. To test 
this we performed an in vitro kinase assay with the addition 
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Figure 4: In ER+ T47D breast cancer cells MDM2 influences estrogen mediated cell proliferation through the Rb-E2F1 
pathway. (A) Inducible clonal T47D cells with mdm2 shRNA or control vector were treated with or without 4μg/ml doxycycline (dox) for 
3 days, followed by 10nM estrogen for 5 days in the presence or absence of dox. A representative image of western blot analysis of MDM2, 
phospho Rb, E2F1, p53 and Actin protein levels from 50μg whole cell protein extract is shown. (B) ImageJ analysis was performed for 
MDM2, phospho Rb and E2F1 protein levels normalized to Actin. The graph represents an average of three independent experiments with 
standard deviation in inducible clonal T47D cells with mdm2 shRNA or control vector. (C) A constitutive pool of T47D cells with mdm2 
shRNA or control vector were grown with or without 10nM estrogen for 5 days. A representative image of western blot analysis of MDM2, 
phospho Rb, E2F1, total Rb and Actin protein levels from 50μg whole cell protein extract is shown. (D) ImageJ analysis was performed 
for MDM2, phospho Rb and E2F1 protein levels normalized to Actin. Graph represents average of three independent experiments with 
standard deviation in constitutive pool of T47D cells with mdm2 shRNA or control vector. * represents a p-value ≤ 0.05, ** represents a 
p-value ≤ 0.01, *** represents a p-value ≤ 0.001. The p-value was determined by 2-tailed Student t-test.
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of bacterially purified MDM2 to MCF7 and T47D cancer 
cell extract from cells grown with or without overnight 
estrogen treatment. We observed that MCF7 cell extract 
(Figure 6D on the left) supported increased phosphorylation 
of Rb in three independent biological replicates with a 
lower but not higher amount of MDM2 (Figure 6D, left 
side and dot plot for low MDM2 addition shown below). 
The increased MDM2 did not decrease total Rb so less 
phosphorylation of Rb might be due to other alterations in 
post-translational modifications but not degradation. We 
observed a similar (but less robust) result in T47D extract 
(Figure 6D, right side). Taken together, our data suggest that 
estrogen provokes signals to increase MDM2 expression 
and this estrogen stimulated MDM2 promotes signal 
transduction for increasing phosphorylation of Rb.
DISCUSSION
The p53-independent oncogenic functions of 
MDM2 are less well understood than the MDM2 
canonical wild-type p53 feedback pathway. Many breast 
cancers contain no functional wild-type p53 and have 
high expression of MDM2. MDM2 overexpression is 
directly related to ER alpha overexpression [2, 4, 13, 34]. 
A recent analysis of The Cancer Genome Atlas (TCGA) 
invasive breast cancer data found significantly higher 
Figure 5: In ER+ MCF7 breast cancer cells MDM2 influences estrogen mediated cell proliferation through the Rb-E2F1 
pathway. (A) Inducible clonal MCF7 cells with mdm2 shRNA or control vector were treated with and without 2μg/ml doxycycline(dox) 
for 3 days to induce shRNA expression, followed by 10nM estrogen for 5 days in the presence and absence of dox. A representative image 
of western blot analysis of phospho Rb, Total Rb, E2F1, MDM2 and Actin protein levels from 50μg whole cell protein extract is shown. 
(B) ImageJ analysis was performed for phospho Rb, E2F1 and MDM2 protein levels normalized to Actin. Graph represents average of four 
independent experiments with standard deviation in inducible clonal of MCF7 cells with mdm2 shRNA or control vector. * represents a 
p-value ≤ 0.05, ** represents a p-value ≤ 0.01. The p-value was determined by 2-tailed Student t-test.
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mdm2 mRNA in ER alpha-positive tumors without a 
correlation to p53 wild-type or mutant status [13]. This 
analysis also showed that a high ER alpha level correlates 
with increased expression of both MDM2 and MDM4 
and that ER alpha-targeting therapies down-modulate 
both MDM2 and MDM4 expression [13]. We, and others, 
have observed that estrogen provokes p53-independent 
proliferative effects [10, 11, 13, 33]. In this paper we 
present data that suggests that the estrogen-MDM2 axis 
signals a cascade resulting in the phosphorylation of Rb. 
Massive amounts of publicly available breast cancer 
data are available to evaluate the in vivo breast cancer 
Figure 6: Fulvestrant treatment inhibits MDM2 expression and blocks the Rb-E2F1 pathway. (A) T47D.shmdm2 cells were 
treated with 10nM estrogen (lane 1) and either had MDM2 knockdown (lane 2) or 10μM fulvestrant treatment (lane 3), or both (lane 4) for 5 
days. A representative western blot analysis of MDM2, phosphoRb and Actin protein levels from 50μg whole cell protein extract is shown. 
Dot plot diagram shows quantified ImageJ values of phospho Rb protein levels normalized to Actin from three independent experiments. (B) 
MTT assay was performed in T47D.control vector and inducible T47D.shmdm2 clonal cell lines after treatments. Percentage mitochondrial 
activity represents an average of 2 independent experiments. (A) & (B) * represents a p-value ≤ 0.05, *** represents a p-value ≤ 0.001, 
**** represents a p-value ≤ 0.0001. The p-value was determined by 2-tailed Student t-test. (C) A representative live cell image by confocal 
microscopy with 20X objective of T47D.vector and inducible clonal T47D.shmdm2 clonal cell lines after treatments. Red fluorescence 
represents staining with propidium iodide. Blue fluorescence represents staining of nuclear DNA. (D) MDM2 drives phosphorylation of 
Rb in ER+ breast cancer cells. In vitro kinase assay was performed to detect phosphorylation of Rb with or without overnight estrogen 
treatment in either presence or absence of bacterially expressed and purified MDM2 (1μl or 2μl). A representative image of Western blot 
analysis of MDM2, phospho Rb and total Rb protein level from nuclear extract of MCF7 (left) and T47D (right) cells are shown. Dot plot 
diagram shows quantified ImageJ values of phospho Rb protein levels normalized to lamin A from three independent experiments, when 
1μl of purified MDM2 was added to the nuclear extracts of MCF7 (left) and T47D (right) cells. The p-value for MCF7 cells with overnight 
estrogen treatment and addition of purified MDM2 (compare lane 4 to lane 5) was statistically significant. The p-value was determined by 
2-tailed Student t-test.
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relationships between MDM2 and phosphorylated Rb [35]. 
We used the cBioportal http://www.cbioportal.org/ with 
the TCGA breast cancer data from http://cancergenome.
nih.gov/ to evaluate the correlation between MDM2 
protein expression and phosphorylated Rb in patient tumor 
tissue (Supplementary Figure 2). We observed a positive 
correlation between phosphorylated Rb and MDM2 
protein expression (Pearson r = 0.192; p-value=0.0638) 
and a negative correlation between total Rb and MDM2 
protein expression (Pearson r = -0.108; p-value=0.2983). 
The correlation between MDM2 and phosphorylated Rb 
was strengthened by the fact that high MDM2 did not have 
a strong correlation with changes in total Rb. This argues 
for a true relationship between increased MDM2 in breast 
cancers and the activation of the Rb-E2F1 pathway. Our 
data support that an estrogen-MDM2 axis activates the 
Rb-E2F1 pathway in at least a subset of breast cancers.
We examined estrogen-driven breast cancer 
cell growth in 3D culture and asked if MDM2 was 
necessary for the hormone-dependent growth properties. 
Interestingly we found that growth of MCF7 and T47D 
cells in soft agar in the presence of estrogen required 
MDM2 expression. The knockdown of MDM2 prevented 
cells with either wild-type p53 or mutant p53 from 
achieving estrogen-mediated anchorage independent cell 
growth. This not only demonstrated that estrogen was 
signaling through up-regulation of MDM2 for mammary 
tumorigenic related phenotypes but also that MDM2 
provided this function in the absence of promoting the 
degradation of p53. We studied the p53-independent 
MDM2-mediated cell morphology in more depth by 
examining the influence of MDM2 on estrogen-mediated 
growth in a laminin rich matrigel environment. We 
observed that MDM2 expression was required for the lack 
of luminal clearance that associates with breast cancer cell 
growth in matrigel and that knockdown of MDM2 resulted 
in luminal clearance. This is the first report of estrogen 
working through an MDM2 pathway, which leads to the 
disruption of mammary architecture, and signaling for 
the phosphorylation of Rb (see model in Figure 7). Our 
preliminary data with the triple negative breast cancer 
(TNBC) cell line MDA-MB-231 suggests no influence 
of MDM2 on proliferation in the absence of receptor 
signaling. The knockdown of MDM2 in estrogen receptor 
negative (ER-) MDA-MB-231 cells did not decrease cell 
proliferation (Supplementary Figure 3). Therefore in T47D 
and MCF7 cells there may be some MDM2-mediated 
cross-talk with estrogen driven factors.
Estrogen signaling has been shown to up-regulate 
Rb phosphorylation [25] and MDM2 decreases total Rb 
while increasing phosphorylated Rb [21, 26]. However 
there has never been a connection made showing that 
the estrogen axis requires signaling to MDM2 for Rb 
phosphorylation thus indicating an estrogen-MDM2-Rb-
E2F1 axis. We observed that MDM2 was required in T47D 
and MCF7 cells in order for estrogen to stimulate the 
phosphorylation of Rb. Interestingly while we observed 
an increase in phosphorylated Rb, we did not observe a 
decrease in total Rb. We have demonstrated for the first 
time that there is an estrogen-MDM2-Rb-E2F1 axis in 
some breast cancer cells.
Figure 7: Schematic representation of MDM2 signaling pathway showing a p53-independent function of MDM2 is 
required for estrogen mediated breast cancer proliferation and disruption in 3D mammary architecture. Model showing 
that MDM2 is a central hub in estrogen signaling and works through an Rb-E2F1 pathway to promote proliferation. Breast cancer cells 
harboring SNP309 have increased binding of the transcription factor Sp1, which causes elevated MDM2 protein levels. Fulvestrant blocks 
the MDM2 pathway and the Rb-E2F1 pathway.
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Fulvestrant is a novel hormone receptor antagonist 
that causes rapid degradation of both the ER and the 
progesterone receptor (PgR) [36] and has been shown to 
be highly effective for treating late stage breast cancer 
[37]. Mechanistically, fulvestrant can block the estrogen 
mediated increased in MDM2 [13, 33]. We observed that in 
addition to blocking the up-regulation of MDM2, fulvestrant 
also downregulated Rb phosphorylation. Moreover, the 
combination of fulvestrant with MDM2 knockdown caused 
a slight reduction in phosphorylated Rb beyond fulvestrant 
alone (although not statistically significant). We observed that 
the addition of MDM2 to breast cancer cell extracts in vitro 
modestly increased the phosphorylation of Rb. However, 
only low and not high MDM2 increased Rb phosphorylation. 
It is possible that a fine tuned regulation of ubiquitination 
activates Rb phosphorylation while increased ubiquitination 
blocks Rb phosphorylation. MDM2 has been shown to 
ubiquitinate Rb and the level of ubiquitination is reduced 
by the deubiquitinase HAUSP [38]. MDM2 knockdown 
and fulvestrant treatment reduced Rb phosphorylation. 
Fulvestrant blocks estrogen-mediated increases in MDM2 by 
increasing MDM2 protein turnover [33]. Fulvestrant alone 
causes G1 cell cycle arrest that is p53-independent and our 
live cell confocal microscopy indicated that this fulvestrant 
and/or MDM2 knockdown did not increase cell death. Our 
data supports the use of fulvestrant as a way to target the 
estrogen-MDM2 signal transduction pathway. Combination 
of fulvestrant with doxorubicin, etoposide or paclitaxel is 
synergistic for inhibiting breast cancer proliferation and 
induces cell death by suppressing MDM2 expression [33]. 
The results presented here support the idea that targeting 
the MDM2 pathway by fulvestrant treatment of estrogen-
receptor positive breast cancers that are not resistant to 
fulvestrant may be an excellent mechanism to target the 
cancer at multiple estrogenic hubs. New MDM2 targeting 
agents are in clinical trials. Fulvestrant resistant ER-positive 
breast cancers have reduced ER and increased ERBB2 [39]. 
Such resistant breast cancers pose a challenge and it will be 
interesting to see if fulvestrant resistant breast cancers have 
up-regulation of MDM2. If fulvestrant-resistant cancers have 
up-regulated MDM2 they might be excellent candidates for 
treatment with MDM2 blocking therapies.
MATERIALS AND METHODS
Cell culture
2D culture: Human breast cancer cells T47D (mdm2 
SNP309 G/G, mutant p53 L194F), MCF7 (mdm2 SNP309 
T/G, wild-type p53), and MDA-MB-231 (mdm2 SNP309 
T/G, mutant p53 R280K) cells were obtained from American 
Type Culture Collection (ATCC). They were grown in 
DMEM (Invitrogen), supplemented with 10% fetal bovine 
serum (FBS, Gemini) and 50U/ml penicillin and 50μg/ml 
streptomycin (Mediatech) at 5% CO2 in a 37
oC humidified 
incubator. Cell lines with the inducible mdm2 knockdown 
were generated as described previously [11]. A T47D cell 
pool with constitutive knockdown of mdm2 was generated 
for this work by infection with MLP vector (a generous gift 
from Scott Lowe) containing mdm2 151656 shRNA or empty 
vector by the retroviral mediated gene transfer method. In 
short, empty or shmdm2 containing vector were transfected 
using the calcium phosphate method to Phoenix packaging 
cells to make virus that was used to infect T47D cells and 
then they were selected with 5μg/ml puromycin.
Anchorage independent growth assay
Cells were grown in 2D culture for 3 days with 
or without doxycycline. They were trypsinized, washed 
with 1X clear HBSS three times and then counted. 
Cells with equal seeding densities were mixed with 
0.3% Noble Agar (Sigma A5431) in phenol-red-free-
DMEM media containing 10% charcoal stripped FBS 
(Gemini), antibiotics, 10nM estrogen and with or without 
doxycycline. They were seeded onto 35mm dishes coated 
with 0.5% Nobel agar in the same media. They were 
then toped with the same media. Estrogen-treated growth 
medium with or without doxycycline was replaced every 
3 days. Colonies were counted after 3-3.5 weeks.
Cell culture in matrigel
Cells were grown in 2D culture for 3 days with 
or without doxycycline. They were trypsinized, washed 
with 1X clear HBSS three times and then counted. They 
were seeded on top of 40μl solidified matrigel (Cultrex) in 
phenol-red-free-DMEM media containing 10% charcoal 
stripped FBS (Gemini), antibiotics, 10nM estrogen and 
with or without doxycycline. Medium was changed 
every 3 days. Masses were grown for 3-3.5 weeks, fixed 
with 4% paraformaldehyde, permeabilized, blocked and 
stained with propidium iodide or actin immunostaining 
by Rhodamine-Phalloidin (Cytoskeleton BK005) or 
primary antibody phospho histone H3 (Millipore) 
followed by Alexa Fluor conjugated secondary antibody 
(Invitrogen) and mounted with Vectashield mounting 
medium containing DAPI (Fisher Scientific). Imaging was 
performed using confocal microscope using laser scanning 
spectral confocal microscope TCS SP2.
Treatments
Inducible shmdm2 or vector control cell lines were 
grown in complete media described above, with or without 
doxycycline (4μg/ml for T47D, and 2μg/ml for MCF7, 
and 6μg/ml for MDA-MB-231) for shRNA induction 
for 3 days. The growth medium was then replaced with 
phenol-red-free DMEM media containing 10% charcoal 
stripped FBS (Gemini) and antibiotics and treated with 
10nM estrogen (17-beta-estradiol, Sigma) and/or 10μM 
fulvestrant (Sigma-Aldrich) wherever applicable. Fresh 
medium was applied every 72 hours.
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MTT assay
Cell viability was often measured as mitochondrial 
activity using tetrazolium dye-based microtitration assay. 
Cells were seeded at 20 x 103 per well in 12-well plate. 
After treatment, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was performed as per 
manufacturers instructions (Sigma). The absorbance was 
quantified by measuring absorbance at 550nm (the 620nm 
absorbance was subtracted from the background). Data 
represent percentage mitochondrial activity in each sample 
relative to the untreated sample.
Live cell imaging
Cells were seeded at 20 x 103 per well in a 12-well 
glass bottom plate (MatTek, Ashland, MA, USA). After 
treatment, cells were stained with 50 ul ReadyProbes 
Cell Viability Imaging Kit Blue/Red (Life Technologies 
Cat# R37610) for 15 min at room temperature and z-stack 
images of stained cells were taken by confocal microscopy 
using a Nikon A1 confocal microscope with 20x objective. 
Maximum projection images are shown. Propidium 
iodide: red fluorescence; Nuclear DNA: blue fluorescence.
Fluorescence activated cell sorting (FACS)
FACS was performed on FACScan device (BD 
Biosciences). After treatments, cells were harvested, 
washed, resuspended in PBS containing 2% bovine serum 
albumin, 0.1% sodium azide, fixed in 30% ethanol and 
stored overnight at 4oC. Before sorting, propidium iodide 
staining and RNAse treatment were performed for 30 
minutes at 37oC.
Whole cell protein extract
Cells were pelleted from 2D culture at 1100 rpm 
for 7 mins at 4oC and washed 3 times with 1X ice-cold 
PBS. The cells were then suspended in RIPA buffer (0.1% 
SDS, 1% IGEPAL NP-40, 0.5% Deoxycholate, 150mM 
NaCl, 1mM EDTA, 0.5mM EGTA, 50mM Tris-Cl pH8) 
with 1mM PMSF, 8.5μg/ml Aprotinin, 2μg/ml Leupeptin, 
sodium fluoride (5mM), sodium orthovanadate (1mM) and 
phosphatase cocktail inhibitor (Sigma) following standard 
protocol.
Purification of MDM2 expressed in bacteria
After IPTG induction for 4 hours, BL21DE3 
(having plasmid pRSETA HDM2; generous gift from 
Lindsey Mayo lab) bacterial cell pellets were collected 
and lysed with lysis buffer (pH 8: 100mM Na2H2PO4, 
10mM Tris-Cl, 8M Urea, 1mM PMSF) by frequent 
vortexing. It was then centrifuged for 25 minutes in 4oC 
at 10,000g. The supernatant was collected, mixed with 
Ni-NTA agarose beads (Qiagen, #30210) in the ratio of 
1:3 (bead to supernatant) and rocked for an hour at 4oC. 
After a quick spin as the beads settled, the supernatant 
was transferred and labeled as “unbound”. The pellet was 
washed with wash buffer (pH 6.3: 100mM Na2H2PO4, 
10mM Tris-Cl, 8M Urea, 1mM PMSF) in 1:2 (bead to 
buffer) 2 times and the supernatant was labeled as “wash”. 
The remaining pellet was mixed in 2.5 X the elution buffer 
(pH 5.9: 100mM Na2H2PO4, 10mM Tris-Cl, 8M Urea, 
100mM EDTA pH8, 1mM PMSF) and supernatant was 
collected after quick spun and labeled as “elute”. This was 
repeated 2 more times. Small aliquots were taken at each 
elution and run on a gel to confirm purification of MDM2 
compared to wash and unbound. The third elute of purified 
MDM2 was used in in vitro kinase assay.
Nuclear extracts
Pellets were collected of cells with and without 
overnight estrogen treatment. The pellets were suspended 
in 5X packed cell volumes with cytoplasmic extraction 
buffer (CEB: 10mM Hepes pH 7.9; 1.5mM MgCl2; 10mM 
KCl; 0.5mM PMSF, 0.5 mM DTT; 8.5μg/ml Aprotinin, 
2μg/ml Leupeptin; and phosphatase inhibitor mixture I 
(Sigma)). After washing, cells were resuspended with 
a 20-gauge needle in 2X packed cell volumes of CEB 
and incubated on ice for 10 min. After centrifugation 
(10 min at 12,000 rpm at 4 °C) the supernatant was 
removed to give the cytoplasmic fraction. The pellet was 
resuspended in kinase reaction buffer (20 mmol/L Tris 
pH 7.5; 7.5 mmol/L MgCl2; 1 mmol/L DTT; 0.5 mmol/L 
ethyleneglycol-bis [beta-aminoethyl]-N,N,N′,N′-tetraacetic 
acid [EGTA]; 25 mmol/L beta-glycerophosphate; 0.5 
mmol/L sodium orthovanadate; 1 mmol/L PMS; 2 μg/ml 
leupeptin, 1.5 μg/ml aprotinin and phosphatase inhibitor 
mixture). Cells were resuspended with a 20-gauge needle 
and the cell suspension was rocked for 30 min at 4 °C and 
then centrifuged for 30 min at 13,000 rpm at 4 °C. The 
supernatant was the nuclear fraction.
In vitro kinase assay
The breast cancer cell nuclear extract made in kinase 
buffer was incubated with 1μl or 2μl of purified MDM2 
in elution buffer or elution buffer alone (control) and 
ATP regeneration system (1mM ATP, 1mM magnesium 
chloride, 10mM phosphocreatine, 50μg/ml creatine 
kinase) for 30 minutes at 30oC. The total reaction volume 
was 50μl. The reaction was terminated with 4X NuPAGE 
Lithium dodecyl Sulfate buffer (Life Technologies) and 
western blot assay was performed immediately.
Western blot assay
Protein extracts from 2D culture were prepared 
with 4X NuPAGE Lithium dodecyl Sulfate buffer (Life 
Technologies) and 20mM DTT. The samples were heated 
at 70oC for 10 min and then 100 mM Iodoacetamide 
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(Sigma) was added after heating. Samples were separated 
by SDS-PAGE followed by electrotransfer onto a 
nitrocellulose membrane. The resulting membrane was 
blocked with 5% non-fat milk (Biorad) in 1X PBS-
0.1% Tween-20 or 5% Bovine Serum Albumin (BSA) 
in 1X TBS-0.1% Tween-20 (for probing phospho Rb) 
and probed with primary antibody overnight at 4oC. The 
membrane was washed with 1X PBS-0.1% Tween-20 
or 1X TBS-0.1% Tween-20 followed by probing with 
secondary antibody. The protein signal was detected by 
chemiluminescence using the Super Signal Kit (Pierce) 
and autoradiography using Hyblot CL films (Denville 
Scientific).
Antibodies
AntiMDM2 antibody – 1:1:1 mix of mouse 
monoclonal antibodies 4B2, 2A9, 4B11; antip53 antibody 
- 1:1:1 mix of mouse monoclonal antibodies 240,421,1801; 
rabbit polyclonal antiActin (Sigma-Aldrich) or anti-
Actin HRP (Santa Cruz); phospho Rb (Ser807/811: Cell 
Signaling); Total Rb (Cell Signaling); E2F1 (Cell Signaling) 
and secondary anti-mouse and anti-rabbit antibodies 
(Sigma-Aldrich) were used for western blot analysis.
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